16 Dec 2021 07:00
16 December 2021
Fusion Antibodies plc
("Fusion" or the "Company")
Exercise of share options and total voting rights
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces an exercise of share options in the Company ("Ordinary Shares") by Sonya Ferguson, Non-Executive Director of the Company.
On 15 December 2021, Sonya Ferguson exercised 25,000 share options. These historic share options were granted prior to the Company's admission to trading on AIM and with an exercise price of 4 pence per share. The new Ordinary Shares issued pursuant to this exercise will be admitted to trading on AIM pursuant to the Block Admission announced by the Company on 27 September 2021. The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Following the above exercise of 25,000 share options, Sonya Ferguson holds 92,567 Ordinary Shares, representing approximately 0.35 per cent. of the Company's enlarged issued share capital.
Following the exercise of share options, the total number of Ordinary Shares in issue is now 25,963,280. The Company does not currently hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 25,963,280, which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
The following notification, made in accordance with the requirements of the UK Market Abuse Regulation, gives further details.
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Sonya Ferguson | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Fusion Antibodies plc | ||||
b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of 4p each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 | ||||
b) | Nature of the transaction | Exercise of share options
| ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information |
| ||||
| - Aggregated volume
| 25,000 | ||||
| - Price
| £0.04
| ||||
e) | Date of the transaction | 15 December 2021
| ||||
f) | Place of the transaction | Outside a trading venue | ||||
Enquiries:
Fusion Antibodies plc | www.fusionantibodies.com | |
Richard Jones, Chief Executive Officer | Via Walbrook PR | |
James Fair, Chief Financial Officer |
| |
|
| |
Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
James Reeve / Vivek Bhardwaj (Corporate Finance) |
| |
Tony Quirke (Sales and Corporate Broking) |
| |
|
| |
Walbrook PR | Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
| ||
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.
Fusion Antibody (FAB)